Friday, November 17, 2017 11:17:40 AM
Couple of points.
1.) Management did not "bail". I was placed as Chief Innovation Officer who's job was change management. We identified issues and pivoted the business as needed. In other words, we dropped what wasn't working and added new management as was needed to fix the problems that did exist. I'm the founder and I'm still very much involved. The entire pivot was managed by myself. I in fact wrote an article about the problems that are facing the vertical farming industry, which is the segment we dropped. https://www.linkedin.com/pulse/vertical-farming-industry-learning-from-its-mistakes-chad-sykes/
2.) Tangiers has an attractive PIPE setup, but it's no different than the majority of OTC companies. This type of financing structure has worked out well for AMMJ and CNAB to date allowing them to raise millions. You're welcome to go dig up their filings, note the date of transactions and compare to a historical chart. Tangiers has been a great partner when the Companies deliver.
It's on the company and the new management team to now deliver on its new business efforts. We dropped what wasn't working, shifted focus to our core assets, dramatically reduced expenses (see filings), added a subsidiary that is a pending applicant in Texas, put in place strategic partnerships and now have a funding partner in place. It's not a matter of if we will get a license to produce cannabis, but when. We discussed some of the challenges in our MD&A section of the recent 10Q.
I personally believe interest is low due to the lack of liquidity in the stock rather than any fundamental concerns and I'm hoping that problem will slowly begin to improve.
Warm Regards,
Chad Sykes
Founder, Chief of Cultivation
Indoor Harvest Corp
Recent INQD News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/01/2023 07:35:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2023 01:00:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 02:46:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2023 12:10:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2023 10:02:30 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM